Dr. Muss Discusses Evaluating Cardiac Toxicity in Patients With Breast Cancer

Hyman B. Muss, MD
Published Online: Monday, May 12, 2014
Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluating cardiac toxicity in patients with breast cancer.

Oncologists are now used to doing echocardiograms, which do not require any isotopes and yield rich results, or multigated acquisition (MUGA) scans, which yield results as one simple number.

Muss hypothesizes that in 5-10 years, the best way to monitor cardiac toxicity may be with an MRI of the heart and that those who are researching heart MRI are seeing incredible results.

Online CME Activities
Free CME from PER
Angiogenesis Inhibitors for Gastrointestinal Cancers: Update From the 2015 Gastrointestinal Cancers Symposium
Cancer Summaries and Commentaries™: Updates from San Francisco in Acute Myeloid Leukemia
Community Practice Connections: 9th Annual New York Lung Cancer Symposium®
Recap of SABCS 2014: Changes for Today and Hope for Tomorrow
More Reading
$auto_registration$